Published Year: 2023
Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Market Outlook
1.1.1 Market Overview
1.1.2 Product Definition
1.1.3 Inclusion and Exclusion Criteria
1.1.4 Key Findings
1.2 Industry Outlook
1.2.1 Key Trends
1.2.1.1 Significant Number of Collaborations among Market Players
1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
1.2.2 Opportunity Assessment
1.2.3 Patent Analysis
1.2.3.1 Awaited Technological Developments
1.2.3.2 Patent Filing Trend (by Country)
1.2.3.3 Patent Filing Trend (by Year)
1.2.4 Production Capability
1.2.5 Preferred Techniques By CDMO
1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
1.2.6 Factors Considered While Outsourcing To CDMO.
1.2.7 Regulatory Framework
1.3 Impact of COVID-19 on the Nucleic Acid Therapeutics CDMO
1.3.1 Pre-COVID-19 Phase
1.3.2 During COVID-19
1.3.3 Post-COVID-19 Phase
1.3.3.1 Impact on Demand and Supply
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti?Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
1.6.3 MicroRNAs (miRNAs)
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Business Dynamics
1.7.1 Impact Analysis
1.7.2 Business Drivers
1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
1.7.3 Business Restraints
1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
1.7.4 Business Opportunities
1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented
2.1 Europe Nucleic Acid Therapeutics CDMO Market
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
2.1.3.2.1 Germany
2.1.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.2 U.K.
2.1.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.3 France
2.1.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.4 Spain
2.1.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.5 Italy
2.1.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.6 Rest-of-Europe
2.1.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnerships and Collaborations
3.1.1.5 Business Expansions
3.1.1.6 Regulatory and Legal Activities
3.1.2 Market Share Analysis
3.1.3 Visual Graphics of Key Companies
3.2 Company Profile
3.2.1 AGC Biologics
3.2.1.1 Company Overview
3.2.1.2 Role of AGC Biologics in the Nucleic Acid Therapeutics CDMO Market
3.2.1.3 Financials
3.2.1.4 Recent Developments
3.2.1.5 Analyst Perspective
3.2.2 BACHEM
3.2.2.1 Company Overview
3.2.2.2 Role of BACHEM in the Nucleic Acid Therapeutics CDMO Market
3.2.2.3 Financials
3.2.2.4 Recent Developments
3.2.2.5 Analyst Perspective
3.2.3 Eurofins Scientific
3.2.3.1 Company Overview
3.2.3.2 Role of Eurofins Scientific in the Nucleic Acid Therapeutics CDMO Market
3.2.3.3 Financials
3.2.3.4 Recent Developments
3.2.3.5 Analyst Perspective
3.2.4 LGC Science Group Holdings Limited
3.2.4.1 Company Overview
3.2.4.2 Role of LGC Science Group Holdings Limited in the Nucleic Acid Therapeutics CDMO Market
3.2.4.3 Recent Developments
3.2.4.4 Analyst Perspective
3.2.5 Merck KGaA
3.2.5.1 Company Overview
3.2.5.2 Role of Merck KGaA in the Nucleic Acid Therapeutics CDMO Market
3.2.5.3 Financials
3.2.5.4 Recent Developments
3.2.5.5 Analyst Perspective
Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
Table 2: Key Questions Answered in the Report
Table 3: Some of the Partnerships and Collaborations in the Nucleic Acid Therapeutics CDMO Market
Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment
Table 5: Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
Table 7: Advancements in Manufacturing Units of CDMO
Table 8: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
Figure 1: Services Offered by CDMOs
Figure 2: Europe Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 3: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
Figure 5: Europe Nucleic Acid Therapeutics CDMO Market: Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023
Figure 10: Core CDMO Services
Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
Figure 12: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
Figure 13: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
Figure 14: Synthesis Capabilities of Key Companies
Figure 15: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
Figure 16: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
Figure 17: Preferred Techniques by CDMOs for Nucleic Acid Purification
Figure 18: Factors considered while outsourcing to CDMO.
Figure 19: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 20: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
Figure 21: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Nucleic Acid Therapeutics CDMO Market, 2018-2020
Figure 22: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
Figure 23: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 24: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 25: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
Figure 26: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 27: Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 28: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 29: U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 30: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 31: France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 32: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 33: Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 34: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 35: Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 36: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 37: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 38: Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
Figure 39: Funding Activities, January 2018-February 2023
Figure 40: New Offerings, January 2018-February 2023
Figure 41: Mergers and Acquisitions, January 2018-February 2023
Figure 42: Partnerships and Collaborations, January 2018-February 2023
Figure 43: Business Expansions, January 2018-February 2023
Figure 44: Regulatory and Legal Activities, January 2018-February 2023
Figure 45: Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
Figure 46: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
Figure 47: AGC Biologics: Product Portfolio
Figure 48: AGC Biologics: Overall Financials, $Million, 2019-2021
Figure 49: AGC Biologics: Segment Revenues, $Million, 2019-2021
Figure 50: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
Figure 51: BACHEM: Product Portfolio
Figure 52: BACHEM: Overall Financials, $Million, 2020-2022
Figure 53: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
Figure 54: BACHEM: Net Revenue (by Region), $Million, 2020-2022
Figure 55: BACHEM: R&D Expenditure, $Million, 2020-2022
Figure 56: Eurofins Scientific: Product Portfolio
Figure 57: Eurofins Scientific: Overall Financials, $Million, 2020-2022
Figure 58: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
Figure 59: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
Figure 60: LGC Science Group Holdings Limited: Product Portfolio
Figure 61: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
Figure 62: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
Figure 63: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
Figure 64: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
Figure 65: Merck KGaA: Product Portfolio
Figure 66: Merck KGaA: Overall Financials, $Million, 2020-2022
Figure 67: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
Figure 68: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
Figure 69: Merck KGaA: R&D Expenditure, $Million, 2020-2022
Europe Nucleic Acid Therapeutics CDMO Market Report Coverage
|
Europe Nucleic Acid Therapeutics CDMO Market |
|||
|
Base Year |
2022 |
Market Size in 2023 |
$1.27 Billion |
|
Forecast Period |
2023-2033 |
Value Projection and Estimation by 2033 |
$3.88 Billion |
|
CAGR During Forecast Period |
11.80% |
||
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.
Some prominent names established in this market are:
• AGC Biologics
• BACHEM
• Eurofins Scientific
• LGC Science Group Holdings Limited
• Merck KGaA
How can this report add value to the organization?
Product/Innovation Strategy: The Europe nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as chemical synthesis method and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: Key players in the Europe nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.
Introduction to Europe Nucleic Acid Therapeutics CDMO Market
The Europe nucleic acid therapeutics CDMO market was valued at $1.27 billion in 2023 and is expected to reach $3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033. The nucleic acid therapeutics CDMO market is experiencing growth due to various factors, these include increasing demand for nucleic acid therapeutics in treating chronic and genetic illnesses, advancements in manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs), a surge in FDA approvals for such therapeutics, and growing investments in expanding CDMO manufacturing capacities.
Market Introduction
The Europe nucleic acid therapeutics Contract Development and Manufacturing Organization (CDMO) market is witnessing significant growth. This expansion is driven by a rising demand for nucleic acid-based treatments to address chronic and genetic diseases prevalent in the region. Additionally, advancements in manufacturing processes by CDMOs are enhancing the production efficiency and scalability of nucleic acid therapeutics. The region has also seen an uptick in FDA approvals for these therapies, indicating growing acceptance and adoption. Moreover, increased investments in expanding CDMO manufacturing facilities across Europe are further fueling market growth. This dynamic landscape underscores the region's commitment to innovation and healthcare advancement, positioning Europe as a key player in the global nucleic acid therapeutics CDMO market.
Market Segmentation:
Segmentation 1: by Chemical Synthesis Method
• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis
Segmentation 2: by Country
• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe
Europe Nucleic Acid Therapeutics CDMO Market
Analysis and Forecast, 2023-2033
Some Faq's
Frequently Asked Questions
Pharmaceutical companies involved in the manufacturing, and commercializing of drugs, should buy this report.
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033
CDMO stands for Contract Development and Manufacturing Organization. In biotech, CDMOs provide services to pharmaceutical and biotechnology companies, offering expertise in drug development, manufacturing, and related processes on a contractual basis. They assist in bringing new therapies to market efficiently by leveraging their specialized capabilities and infrastructure.
Nucleic acid-based therapeutics are medications that utilize nucleic acids, such as DNA or RNA, to treat diseases. They work by targeting specific genes or gene products involved in disease processes, aiming to modify gene expression, regulate protein production, or correct genetic abnormalities, offering promising treatments for various medical conditions.
Antisense oligonucleotides: Inhibit gene expression by binding to target mRNA.
siRNA (small interfering RNA): Silence specific genes by triggering mRNA degradation.
mRNA (messenger RNA): Deliver genetic instructions for protein synthesis.
Gene editing tools (e.g., CRISPR/Cas9): Modify genomic DNA to correct or alter genetic sequences.
Similar Product
You may also like